arrow
C

Chloe Orkin

Queen Mary University of London
H指数:63
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial

在HIV感染者男性接受分析性治疗中断期间的中和抗体:RIO试验II期随机对照试验的次要和探索性结局

2026-09-150
OAAI
Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial

从复杂HIV方案转换为单片制剂bictegravir–lenacapavir(ARTISTRY-1):一项随机、开放标签、III期临床试验

2026-02-250
OAAI
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

在接受口服抗逆转录病毒治疗的HIV-1的病毒学抑制成人中,每天一次改用固定剂量的doravirine (100 mg) 和islatravir (0·25 mg): 3期,多中心,随机,开放标签,非劣效性试验的48周结果

2026-02-050
PRE
Outcomes of real-world initiation of long-acting injectable cabotegravir and rilpivirine (LA-I CAB plus RPV) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations

真实世界中长期作用注射用卡博格韦和 rilpivirine(LA-I CAB plus RPV)在伴有病毒血症个体中的启动结局:一项关于基线特征、病毒学失败结局和停药情况的系统综述

2025-09-010
OAAI
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process

建立长效注射用卡博格韦和 rilpivirine 治疗的病毒学失败和停药共享定义(CONSENSUS-LAI 研究):一项国际调查和德尔菲过程

2025-08-040
OAAI
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions

优化卡博格韦尔联合 rilpivirine 长效疗法在 HIV 管理中的应用:证据、实施及未解决的问题

2025-07-012
OAAI
Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV

长效注射用卡博格韦和拉米夫定在观察性队列研究中的使用:关于病毒抑制的HIV感染者病毒学失败、耐药性及病毒再抑制结局的系统评价

2025-06-130
OAAI
The (Re)-emerging And ePidemic Infectious Diseases (RAPID) Stigma Scales: a cross-outbreak scale development and pyschometric validation study

《(Re)-emerging And ePidemic Infectious Diseases (RAPID) 耻辱感量表:一项跨疫情量表的开发与心理测量学验证研究》

2025-05-300
PRE
Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV

Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)在病毒学事件后的疗效:一项针对HIV感染者人群研究的合并分析

2025-04-150
OA
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies

Bictegravir/emtricitabine/tenofovir alafenamide在启动一线治疗的HIV-1感染的黑人和西班牙裔/拉丁裔成人中的疗效与安全性:两项III期研究的5年随访结果

2025-03-210
OAAI